This is a StreetInsider.com Premium Only Page

(BBIO) – Company Press Releases

Apr 10, 2024 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 7, 2024 01:15 PM BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardi

Mar 20, 2024 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 5, 2024 11:53 PM BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

Mar 4, 2024 04:17 PM BridgeBio Pharma Announces Proposed Public Offering of Common Stock

Mar 4, 2024 02:30 AM BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

Feb 22, 2024 07:30 AM BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Feb 7, 2024 07:34 AM BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

Feb 6, 2024 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Feb 5, 2024 07:30 AM BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR

Feb 2, 2024 07:00 AM BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial

Jan 30, 2024 07:00 AM Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Jan 18, 2024 07:00 AM BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

Jan 10, 2024 05:15 PM BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of

Jan 10, 2024 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2024 04:30 PM BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

Jan 3, 2024 07:30 AM BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

Dec 13, 2023 07:30 AM BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

Dec 8, 2023 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2023 07:44 AM BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (A

Nov 12, 2023 10:30 AM BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Nov 9, 2023 07:30 AM BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessi

Nov 8, 2023 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 2, 2023 07:30 AM BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

Oct 11, 2023 07:30 AM BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2023 07:30 AM BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Oct 9, 2023 07:30 AM BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle

Sep 25, 2023 07:30 AM BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

Sep 8, 2023 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Sep 7, 2023 07:30 AM BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 6, 2023 07:30 AM BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

Aug 27, 2023 06:15 AM BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2

Aug 24, 2023 04:01 PM BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

Aug 4, 2023 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 3, 2023 07:30 AM BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

Jul 31, 2023 07:30 AM BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces Firs

Jul 18, 2023 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 17, 2023 07:00 AM BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Jul 14, 2023 04:01 PM BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023

Jul 12, 2023 04:31 PM Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma

Jun 20, 2023 07:30 AM BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference

Jun 13, 2023 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 8, 2023 07:30 AM BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual

May 22, 2023 07:30 AM BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Mee

May 15, 2023 07:30 AM BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 11, 2023 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 4, 2023 07:30 AM BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update

Apr 27, 2023 07:30 AM BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference

Apr 27, 2023 07:30 AM BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference

Apr 11, 2023 07:30 AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)